One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Two leading medical stocks that appear reasonable at current levels are AbbVie ( ABBV 0.78%) and Merck ( MRK +0.31%). The former has actually beaten the market in 2025, while the latter is in the red ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV virus.